Description

Balchem Corporation: Expanding Product Portfolio with Optifolin+ & Leadership in Chelated Minerals Catapulting Their Growth! 

Balchem Corporation’s second quarter financial results for 2024 reflected a continued robust performance despite a challenging market environment. The quarter witnessed a moderate growth in consolidated revenues, which increased by 1.2% year-over-year to $234 million. This growth was primarily led by significant contributions from the Human Nutrition & Health and Specialty Products segments, which offset the declines observed in the Animal Nutrition & Health segment.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!